{"id":11188,"date":"2025-04-14T13:56:02","date_gmt":"2025-04-14T11:56:02","guid":{"rendered":"https:\/\/www.kliinikum.ee\/yhendlabor\/?page_id=11188"},"modified":"2025-11-26T21:02:01","modified_gmt":"2025-11-26T19:02:01","slug":"cd20-b-rakkudel","status":"publish","type":"page","link":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/","title":{"rendered":"CD20 B-rakkudel"},"content":{"rendered":"\n

Immuunanal\u00fc\u00fcsi osakond<\/em><\/p>\n\n\n\n

CD20<\/strong> on CD19 k\u00f5rval teine peamine B-rakkude diferentseerumise marker. CD20 lisandub B-rakkude pinnale alates pre-B staadiumist, mist\u00f5ttu enamik k\u00fcpseid B-rakke on CD19+\/CD20+. CD20 puudub mittek\u00fcpsetel eellastel ja ka plasmarakkudel.<\/p>\n\n\n\n

CD20 on mitmete autoimmuunhaiguste ja B-rakuliste hematoloogiliste haiguste korral immuunravi m\u00e4rklauaks. CD20-vastaste monoklonaalsete antikehade (Rituximab<\/em>, Obinutuzumab<\/em> jt) toimel B-rakud h\u00e4vivad. Ravimi toime p\u00fcsib mitmeid kuid \u2013 perifeersete B-l\u00fcmfots\u00fc\u00fctide arv taastub esialgsele tasemele umbes 3.\u201312. kuul p\u00e4rast ravimi manustamist.<\/p>\n\n\n\n

CD20 ja CD19 puudulikkust v\u00f5i m\u00e4rgatavat v\u00e4henemist on t\u00e4heldatud primaarse humoraalse immuunpuudulikkuse korral, nagu nt X-seoseline agammaglobulineemia ja autosoomne retsessiivne agammaglobulineemia.<\/p>\n\n\n\n

Uuritav materjal, selle v\u00f5tmine, saatmine ja s\u00e4ilitamine<\/strong><\/p>\n\n\n\n

<\/td>Katsuti<\/strong><\/td>K2E\/K3E-katsuti (lilla kork)<\/td><\/tr>
<\/td>Minimaalne kogus<\/strong><\/td>1 mL venoosset verd<\/td><\/tr>
<\/td>S\u00e4ilivus<\/strong><\/td>Toatemperatuuril kuni 24 tundi. Mitte k\u00fclmutada! Hoida p\u00e4ikesekiirguse eest!<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Anal\u00fc\u00fcsi tegemise aeg:<\/strong> t\u00f6\u00f6p\u00e4eviti, vastus 3 t\u00f6\u00f6p\u00e4eva jooksul<\/p>\n\n\n\n

Anal\u00fc\u00fcsimeetod:<\/strong> vooluts\u00fctomeetria<\/p>\n\n\n\n

Vastuse vorm<\/strong><\/p>\n\n\n\n

CD19+ B-l\u00fcmfots\u00fc\u00fctide arv (CD19 E6\/L)<\/p>\n\n\n\n

CD19+ B-l\u00fcmfots\u00fc\u00fctide suhtarv (CD19%) k\u00f5ikidest l\u00fcmfots\u00fc\u00fctidest<\/p>\n\n\n\n

CD20+ B-l\u00fcmfots\u00fc\u00fctide arv (CD20 E6\/L)<\/p>\n\n\n\n

CD20+ B-l\u00fcmfots\u00fc\u00fctide suhtarv (CD20%) k\u00f5ikidest l\u00fcmfots\u00fc\u00fctidest<\/p>\n\n\n\n

L\u00fcmfots\u00fc\u00fctide absoluutarv  (CD45 E6\/L)<\/p>\n\n\n\n

Referentsv\u00e4\u00e4rtus<\/strong><\/p>\n\n\n\n

V\u00e4ljastatakse koos uuringu tulemusega.<\/p>\n\n\n\n

N\u00e4idustus ja kliiniline t\u00e4hendus<\/strong><\/p>\n\n\n\n

N\u00e4idustus<\/p>\n\n\n\n

    \n
  • CD19+\/CD20+ B-rakkude hindamine anti-CD20 ravi patsientidel<\/li>\n\n\n\n
  • B-rakkude hindamine CD19 puudulikkuse kahtlusega patsientidel (kuni 2% CVID (\u00fcldine variaabel immuunpuudulikkus) patsientidest CD19 geeni mutatsiooniga)<\/li>\n<\/ul>\n\n\n\n

    T\u00f5lgendus<\/p>\n\n\n\n

      \n
    • Anti-CD20 ravi patsientidel CD19+\/CD20+ rakud puuduvad v\u00f5i nende arv on oluliselt v\u00e4henenud v\u00f5rreldes ravieelse n\u00e4itajaga<\/li>\n<\/ul>\n\n\n\n

      Kasutatud kirjandus<\/strong><\/p>\n\n\n\n

        \n
      • Marshall M, et al.<\/em>, Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? Front Immunol, 04 October 2017.<\/li>\n\n\n\n
      • Delgado S., et al<\/em>., Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. Journal of Neurology (2024), 271(4):1515\u20131535.<\/li>\n\n\n\n
      • Payandeh Z. et al<\/em>., The applications of anti-CD20 antibodies to treat various B cells disorders. Biomedicine & Pharmacotherapy, (2019) Jan:109:2415-2426.<\/li>\n<\/ul>\n\n\n\n

        Koostaja: Eva Reinmaa
        Muudetud 09.04.2025<\/p>\n\n\n\n

        <\/p>\n","protected":false},"excerpt":{"rendered":"

        Immuunanal\u00fc\u00fcsi osakond CD20 on CD19 k\u00f5rval teine peamine B-rakkude diferentseerumise marker. CD20 lisandub B-rakkude pinnale alates pre-B staadiumist, mist\u00f5ttu enamik k\u00fcpseid B-rakke on CD19+\/CD20+. CD20 puudub mittek\u00fcpsetel eellastel ja ka plasmarakkudel. CD20 on mitmete autoimmuunhaiguste ja B-rakuliste hematoloogiliste haiguste korral immuunravi m\u00e4rklauaks. CD20-vastaste monoklonaalsete antikehade (Rituximab, Obinutuzumab jt) toimel B-rakud h\u00e4vivad. Ravimi toime p\u00fcsib mitmeid […]<\/p>\n","protected":false},"author":31,"featured_media":0,"parent":7277,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-11188","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nCD20 B-rakkudel - \u00dchendlabor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CD20 B-rakkudel - \u00dchendlabor\" \/>\n<meta property=\"og:description\" content=\"Immuunanal\u00fc\u00fcsi osakond CD20 on CD19 k\u00f5rval teine peamine B-rakkude diferentseerumise marker. CD20 lisandub B-rakkude pinnale alates pre-B staadiumist, mist\u00f5ttu enamik k\u00fcpseid B-rakke on CD19+\/CD20+. CD20 puudub mittek\u00fcpsetel eellastel ja ka plasmarakkudel. CD20 on mitmete autoimmuunhaiguste ja B-rakuliste hematoloogiliste haiguste korral immuunravi m\u00e4rklauaks. CD20-vastaste monoklonaalsete antikehade (Rituximab, Obinutuzumab jt) toimel B-rakud h\u00e4vivad. Ravimi toime p\u00fcsib mitmeid […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00dchendlabor\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T19:02:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/immuunstaatuse-uuringud\\\/cd20-b-rakkudel\\\/\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/immuunstaatuse-uuringud\\\/cd20-b-rakkudel\\\/\",\"name\":\"CD20 B-rakkudel - \u00dchendlabor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\"},\"datePublished\":\"2025-04-14T11:56:02+00:00\",\"dateModified\":\"2025-11-26T19:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/immuunstaatuse-uuringud\\\/cd20-b-rakkudel\\\/#breadcrumb\"},\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/immuunstaatuse-uuringud\\\/cd20-b-rakkudel\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/immuunstaatuse-uuringud\\\/cd20-b-rakkudel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00e4siraamat\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Immuunstaatuse uuringud\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/immuunstaatuse-uuringud\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"CD20 B-rakkudel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\",\"name\":\"\u00dchendlabor\",\"description\":\"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CD20 B-rakkudel - \u00dchendlabor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/","og_locale":"et_EE","og_type":"article","og_title":"CD20 B-rakkudel - \u00dchendlabor","og_description":"Immuunanal\u00fc\u00fcsi osakond CD20 on CD19 k\u00f5rval teine peamine B-rakkude diferentseerumise marker. CD20 lisandub B-rakkude pinnale alates pre-B staadiumist, mist\u00f5ttu enamik k\u00fcpseid B-rakke on CD19+\/CD20+. CD20 puudub mittek\u00fcpsetel eellastel ja ka plasmarakkudel. CD20 on mitmete autoimmuunhaiguste ja B-rakuliste hematoloogiliste haiguste korral immuunravi m\u00e4rklauaks. CD20-vastaste monoklonaalsete antikehade (Rituximab, Obinutuzumab jt) toimel B-rakud h\u00e4vivad. Ravimi toime p\u00fcsib mitmeid […]","og_url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/","og_site_name":"\u00dchendlabor","article_modified_time":"2025-11-26T19:02:01+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/","name":"CD20 B-rakkudel - \u00dchendlabor","isPartOf":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website"},"datePublished":"2025-04-14T11:56:02+00:00","dateModified":"2025-11-26T19:02:01+00:00","breadcrumb":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/#breadcrumb"},"inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/cd20-b-rakkudel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/"},{"@type":"ListItem","position":2,"name":"K\u00e4siraamat","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/"},{"@type":"ListItem","position":3,"name":"Immuunstaatuse uuringud","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/immuunstaatuse-uuringud\/"},{"@type":"ListItem","position":4,"name":"CD20 B-rakkudel"}]},{"@type":"WebSite","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/","name":"\u00dchendlabor","description":"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kliinikum.ee\/yhendlabor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Kaja Vaagen","author_link":"https:\/\/www.kliinikum.ee\/yhendlabor\/author\/kajakall\/"},"uagb_comment_info":0,"uagb_excerpt":"Immuunanal\u00fc\u00fcsi osakond CD20 on CD19 k\u00f5rval teine peamine B-rakkude diferentseerumise marker. CD20 lisandub B-rakkude pinnale alates pre-B staadiumist, mist\u00f5ttu enamik k\u00fcpseid B-rakke on CD19+\/CD20+. CD20 puudub mittek\u00fcpsetel eellastel ja ka plasmarakkudel. CD20 on mitmete autoimmuunhaiguste ja B-rakuliste hematoloogiliste haiguste korral immuunravi m\u00e4rklauaks. CD20-vastaste monoklonaalsete antikehade (Rituximab, Obinutuzumab jt) toimel B-rakud h\u00e4vivad. Ravimi toime p\u00fcsib mitmeid…","_links":{"self":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/11188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/users\/31"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/comments?post=11188"}],"version-history":[{"count":0,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/11188\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/7277"}],"wp:attachment":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/media?parent=11188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}